Predicting glioma survival and extracellular matrix remodeling through MRI radiogenomics.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42127900.
- Also identified by DOI 10.1016/j.xcrm.2026.102775.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Extracellular matrix (ECM) remodeling is essential for glioma invasion, yet lacks non-invasive assessment methods. This study employs radiogenomics to enable non-invasive survival prediction and ECM remodeling assessment in glioma. Utilizing a multi-dataset data (n = 891), an 11-feature radiomics signature is developed stratifying patients into low- and high-Rad-score groups (area under the receiver operator characteristic curve [AUC] = 0.886, 95% confidence interval [CI]: 0.807-0.964 in the training set from two local centers; AUC = 0.828, 95% CI: 0.796-0.893 in the validation set from five public datasets). Radiogenomic analysis (n = 572) reveals differentially expressed genes significantly associated with Rad-scores, particularly enriched in pathways associated with ECM remodeling, and identifies seven related hub genes (MMP2, MMP9, CXCL8, TIMP1, IL-6, COL1A2, and CCL2). These findings are validated using an external radiogenomic dataset and orthotopic (both syngeneic and xenograft) mouse models, where silencing MMP2 reduced Rad-scores and tumor infiltration. This study highlights the potential of MRI-based radiomics signatures in assessing ECM remodeling for survival prediction and improved glioma clinical management.